Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza

por Wang, Yeming, Zhong, Wu, Salam, Alex, Tarning, Joel, Zhan, Qingyuan, Huang, Jian-an, Weng, Heng, Bai, Changqing, Ren, Yanhong, Yamada, Koichi, Wang, Dayan, Guo, Qiang, Fang, Qiongqiong, Tsutomu, Sakurai, Zou, Xiaohui, Li, Haibo, Gillesen, Annelies, Castle, Lyndsey, Chen, Cheng, Li, Hongyan, Zhen, Jing, Lu, Binghuai, Duan, Jun, Guo, Liping, Jiang, Jinfang, Cao, Ruiyuan, Fan, Guohui, Li, Jintong, Hayden, Frederick G., Wang, Chen, Horby, Peter, Cao, Bin
Publicado 2020